Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler
News
Men die more often than women after bariatric surgery
Men undergoing bariatric surgery tend to be older than women and have more comorbidities and perioperative mortality.
News
Primary goal in T2D should be weight loss, diabetologists say
Four diabetes and obesity experts make the case for targeting weight loss of at least 15% as a frontline treatment goal for many patients with...
News
Women with type 2 diabetes get fewer cardioprotective drugs than do men
“This is confirmation that women are less well managed than men when it comes to cardiovascular risk, especially if they have [type 2] diabetes...
News
EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinition
Cardiologists have long defined heart failure as involving reduced or preserved ejection fraction. Results from big empagliflozin trials say...
News
STOP-DAPT 2 ACS: 1 month of DAPT proves inadequate for patients with recent ACS
Findings from a Japanese trial show 1 month of dual antiplatelet therapy and 11 months of clopidogrel monotherapy is inferior to 12 months of DAPT...
News
EMPEROR-Preserved spouts torrent of reports on empagliflozin treatment of HFpEF
The primary report from EMPEROR-Preserved on using empagliflozin to treat patients with HFpEF arrived with four other analyses published in its...
News
FIDELITY: Finerenone benefits patients with T2D across CKD spectrum
FIDELITY, a prespecified analysis of FIDELIO-DKD and FIGARO-DKD, showed finerenone cuts event rates in patients with normal eGFR and albuminuria...
News
EMPEROR-Preserved: Empagliflozin scores HFpEF breakthrough
Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection...
News
FDA okays difelikefalin for dialysis-associated pruritus in patients with CKD
Pruritus in patients with chronic kidney disease on hemodialysis is common and has had no widely accepted go-to treatment.
News
U.S. kidney transplants grow in number and success
Data from 1996 to 2019 show more U.S. kidney transplants recently than ever before, and steady improvements in graft and patient survival.
News
Empagliflozin gets HFrEF approval from FDA
The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes...
News
Tirzepatide questions persist despite serial phase 3 success in type 2 diabetes
Primary results from the SURPASS-3 trial add to accumulating safety and efficacy evidence for the new “twincretin” tirzepatide, but questions...